StageZero Life Sciences Ltd T.SZLS

Alternate Symbol(s): SZLSF

Healthcare Biotechnology

StageZero Life Sciences, Ltd. is a Canada-based vertically integrated healthcare company. The Company is focused on improving the early detection and management of cancer and other chronic diseases through diagnostics telehealth programs. Its lead product, Aristotle, is a mRNA multi-cancer panel for simultaneously screening for multiple cancers from a single sample of blood with high sensitivity and specificity for each cancer. The Care Oncology Clinic offers a supervised treatment regimen for people diagnosed with cancer of any type or stage. AVRT is a physician-led, telehealth program for identifying and managing the early warning signs of cancer and chronic disease. Its program includes a comprehensive online health evaluation; bloodtests to measure markers of inflammation and metabolism; an initial physician consultation; regular physician follow-up appointments and interval screening. Its additional cancer diagnostics include ColonSentry and the Prostate Health Index.

TSX:SZLS - Post by User

StageZero Life Sciences Ltd > Cash

<< Previous

Bullboard Posts

Next >>

Comment by brad129on Jun 22, 2022 4:28pm

162 Views

Post# 34775211

RE:RE:RE:RE:RE:RE:RE:RE:Cash

So what you are acknowledging is sales could be rising at least enough to cover most or all of payroll? Whether it is Care or Aristotle it's irrelevant it's all ours. If we can cover our expenses to almost break even we will skyrocket the share price, then a good size financing for promotional purposes I would have no problem with at all.

Tell me another cancer screening company even close to break even.

Liked2Think wrote:

Maybe that's it. Care is bringing in just enough money to keep payroll going so they can wait until after the vote.

I wonder what the former heads of the before separated care company think now that their company is worth so little now.